Characterising pathways driving aggressive biology and chemoresistance in triple negative breast cancers biology and chemoresistance in triple negative breast cancers

Molecular characterisation and comparison of drug resistant models allowed for the identification of promising druggable targets, whose efficacy in restoring chemosensitivity was assessed via a number of methods, including RNAi, CRISPR, and targeted inhibition. In all, the preliminary identification of a means to sensitise an otherwise highly aggressive cancer to chemotherapeutics, represents an essential step in order to improve current standard of care practices of an otherwise intractable disease.<br><br><br>